July 28, 2015.
India is set to suffer at least $1 billion of loss in export of pharmaceutical products this fiscal following the ban on around 700 generic drugs by the European Commission for alleged manipulation of clinical trials by the Hyderabad-headquartered contract research and clinical trials firm GVK Bio, The Economic Times (India) reports. PV Appaji, the director general of Pharmaceuticals Export Promotion Council (Pharmexcil), said on Monday that the commerce ministry is scheduled to organize consultative discussions with the stakeholders and was weighing options to lodge a compliant with the global agencies against the decision of the European Commission. India exported $15.2 billion (Rs 94,275 crore) of pharmaceutical products in 2014-15, with European Union accounting for a fifth or $3 billion, Appaji added. http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-may-suffer-rs-6300-crore-loss-in-pharma-exports/articleshow/48238880.cms
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.